Circulating antibodies to cysteinyl catecholamines in amyotrophic lateral sclerosis and Parkinson's disease patients

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

Volumn 6, Issue 1 SUPPL. 1, 2005, Pages 226-233

  Salauze, L ^a   van der Velden, C ^a   Lagroye, I ^a   Veyret, B ^a   Geffard, M ^a  

^a Ecole Nationale Superieure de Chimie et de Physique de Bordeaux   (France)

Author keywords

ALS; Circulating antibodies; Cysteinyl catecholamines; Radical species

Indexed keywords

ADRENALIN; CATECHOLAMINE; CYSTEINE; DOPAMINE; HOMOVANILLIC ACID; IMMUNOGLOBULIN G; LEVODOPA; PROTEIN ANTIBODY; CATECHOLAMINE DERIVATIVE; CYSTEINE DERIVATIVE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; ANTIBODY BLOOD LEVEL; ARM DISEASE; BULBAR PARALYSIS; CATECHOLAMINE SYNTHESIS; CIRCULATION; DISEASE COURSE; EXPERIMENTATION; LEG DISEASE;

ADULT; AGED; AGED, 80 AND OVER; AMYOTROPHIC LATERAL SCLEROSIS; ANTIBODIES; CATECHOLAMINES; CYSTEINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 29244453953     PISSN: 14660822     EISSN: 1471180X     Source Type: Journal    
DOI: 10.1080/14660820510044469     Document Type: Article

References (47)

1. Beal, M.F. and Ferrante, R.J. and Browne, S.E. and Matthews, R.T. and Kowall, N.W. and Brown, R.H Jr. (1997) Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Annals of Neurology, 42, pp. 644-654.
2. Bergeron, C. (1995) Oxidative stress: Its role in the pathogenesis of amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 129(Suppl), pp. 81-84.
3. Bertel, O. and Malessa, S. and Sluga, E. and Hornykiewicz, O. (1991) Amyotrophic lateral sclerosis: Changes of noradrenergic and serotonergic transmitter systems in the spinal cord. Brain Research, 566, pp. 54-60.
4. Boullerne, A.I. and Petry, K.G. and Meynard, M. and Geffard, M. (1995) Indirect evidence for nitric oxide involvement in multiple sclerosis by characterization of circulating antibodies directed against conjugated S-nitrosocysteine. Journal Of Neuroimmunology, 60, pp. 117-124.
5. Chou, S.M. and Han, C.Y. and Wang, H.S. and Vlassara, H. and Bucala, R. (1999) A receptor for advanced glycosylation end-products (AGEs) is colocalized with neurofilament-bound AGEs and SOD1 in motor neurons of ALS: Immunohistochemical study. Journal of The Neurological Sciences, 169, pp. 87-92.
6. Clark, F. and Proudfit, H. (1991) The projection of locus coeruleus neurons to the spinal cord in the rat determined by anterograde tracing combined with immunocytochemistry. Brain Research, 538, pp. 231-245.
7. Clark, F. and Proudfit, H. (1991) The projection of noradrenergic neurons in the A7 catecholamine cell group to the spinal cord in the rat demonstrated by anterograde tracing combined with immunocytochemistry. Brain Research, 547, pp. 279-288.
8. Colom, L.V. and Alexianu, M.E. and Mosier, D.R. and Smith, R.G. and Appel, S.H. (1997) Amyotrophic lateral sclerosis immunoglobulins increase intracellular calcium in a motor neuron cell line. Experimental Neurology, 146, pp. 354-360.
9. Colton, C.A. and Gilbert, D.L. (1987) Production of superoxide anions by a CNS macrophage, the microglia. FEBS Letters, 223, pp. 284-288.
10. Daverat, P. and Geffard, M. and Orgogozo, J. M. (1989) Identification and characterization of anti-conjugated azelaic acid antibodies in multiple sclerosis. Journal of Neuroimmunology, 22, pp. 129-134.
11. Drukarch, B. and van Muiswinkel, F.L. (2000) Drug treatment of Parkinson's disease. Time for phase II. Biochemical Pharmacology, 59, pp. 1023-1031.
12. Ferrante, R.J. and Browne, S.E. and Shinobu, L.A. and Bowling, A.C. and Baik, M.J. and MacGarvey, U. et al (1997) Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. Journal of Neurochemistry, 69, pp. 2064-2074.
13. Fornstedt, B. and Bergh, I. and Rosengren, E. and Carlsson, A. (1990) An improved HPLC-electrochemical detection method for measuring brain levels of 5-S-cysteinyldopamine, 5-S-cysteinyl-3,4-dihydroxyphenylalanine, and 5-S-cysteinyl-3,4-dihydroxyphenylacetic acid. Journal of Neurochemistry, 54, pp. 578-586.
14. Fornstedt, B. and Rosengren, E. and Carlsson, A. (1986) Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species. Neuropharmacology, 25, pp. 451-454.
15. Fratantoni, S. and Weisz, G. and Pardal, A. and Reisin, R. and Uchitel, O. (2000) Amyotrophic lateral sclerosis IgG-treated neuromuscular junctions develop sensitivity to L-type calcium channel blocker. Muscle Nerve, 23, pp. 543-550.
16. Geffard, M. and Bodet, D. and Claudepierre, P. and Metzger, J. and Sibilia, J. (1998) Circulating antibodies directed against NO-modified self antigens in chronic neurological and rheumatismal diseases. Immunoanalyse & Biologie Specialisee, 13, pp. 209-217.
17. Geffard, M. and Bodet, D. and Dabadie, M.P. and Arnould, L. (2003) Identification of antibodies in sera of breast cancer patients. Immuno-analyse & Biologie Specialisee, 18, pp. 248-253.
18. Geffard, M. and Bodet, D. and Martinet, Y. and Dabadie, M.-P. (2002) Detection of the specific IgM and IgA circulating in sera of multiple sclerosis patients: Interest and perspectives. Immunoanalyse & Biologie Specialisee, 17, pp. 302-310.
19. Gelinas, S. and Chapados, C. and Beauregard, M. and Gosselin, I. and Martinoli, M.G. (2000) Effect of oxidative stress on stability and structure of neurofilament proteins. Biochemistry and Cell Biology, 78, pp. 667-674.
20. Halliwell, B. (1992) Reactive oxygen species and the central nervous system. Journal of Neurochemistry, 59, pp. 1609-1623.
21. Hastings, T.G. and Zigmond, M.J. (1994) Identification of catechol-protein conjugates in neostriatal slices incubated with [3H]dopamine: Impact of ascorbic acid and glutathione. Journal of Neurochemistry, 63, pp. 1126-1132.
22. Heath, P.R. and Shaw, P.J. (2002) Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve, 26, pp. 438-458.
23. Holstege, J. and Kuypers, H. (1987) Brainstem projections to spinal motor neurons: An update. Neuroscience, 23, pp. 809-821.
24. Ito, S. and Fujita, K. (1982) Conjugation of dopa and 5-S-cysteinyldopa with cysteine mediated by superoxide radical. Biochemical Pharmacology, 31, pp. 2887-2889.
25. Klegeris, A. and McGeer, P.L. (1994) Rat brain microglia and peritoneal macrophages show similar responses to respiratory burst stimulants. Journal of Neuroimmunology, 53, pp. 83-90.
26. LaVoie, M.J. and Hastings, T.G. (1999) Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: Evidence against a role for extracellular dopamine. The Journal of Neuroscience, 19, pp. 1484-1491.
27. LaVoie M.J. and Hastings, T.G. (1999) Peroxynitrite- and nitrite-induced oxidation of dopamine: Implications for nitric oxide in dopaminergic cell loss. Journal of Neurochemistry, 73, pp. 2546-2554.
28. Leanza, G. and Maccavino, M.C. and Stanzani, S. (1996) Noradrenergic neurotransmission in the ventral spinal cord: Basic characteristics and effects of denervating lesions, as studied in the awake rat by microdialysis. Brain Research, 738, pp. 281-291.
29. Llinas, R. and Sugimori, M. and Cherksey, B. and Smith, R. and Delbono, O. and Stefani, E. and Appel, S. (1993) IgG from amyotrophic lateral sclerosis patients increases current through P-type calcium channels in mammalian cerebellar Purkinje cells and in isolated channel protein in lipid bilayer. Proc Natl Acad Sci. USA, 90, pp. 11743-11747.
30. Manabe, Y. and Wang, J. and Murakami, T. and Warita, H. and YHayashi, T. and Shoji, M. and Abe, K. (2001) Expressions of nitrotyrosine and TUNEL immunoreactivities in cultured rat spinal cord neurons after exposure to glutamate, nitric oxide, or peroxynitrite. Journal of Neuroscience Research, 65, pp. 371-377.
31. Pedersen, W.A. and Fu, W. and Keller, J.N. and Markesbery, W.R. and Appel, S. and Smith, R.G. et al (1998) Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. Annals of Neurology, 44, pp. 819-824.
32. Pioro, E.P. (2000) Antioxidant therapy in ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication Of The World Federation Of Neurology, Research Group on Motor Neuron Diseases, 1, pp. 5-12. discussion 13-15
33. Przedborski, S. and Dhawan, V. and Donaldson, D. and Murphy and McKenna-Yasek, D. and Mandel, F. et al (1996) Nigrostriatal dopaminergic function in familial amyotrophic lateral sclerosis patients with and without copper/zinc superoxide dismutase mutations. Neurology, 47, pp. 1546-1551.
34. Rakhit, R. and Cunningham, P. and Furtos-Matei, A. and Dahan, S. and Qi, X.-F. and Crow, J.P. et al (2002) Oxidation-induced misfolding and aggregation of superoxide dismutase and its implications for amyotrophic lateral sclerosis. The Journal of Biological Chemistry, 277, pp. 47551-47556.
35. Shen, X.M. and Dryhurst, G. (1996) Further insights into the influence of L-cysteine on the oxidation chemistry of dopamine: Reaction pathways of potential relevance to Parkinson's disease. Chemical Research in Toxicology, 9, pp. 751-763.
36. Shen, X.M. and Xia, B. and Wrona, M.Z. and Dryhurst, G. Synthesis, redox properties, in vivo formation, and neurobehavioral effects of N-acetylcysteinyl conjugates of dopamine: Possible metabolites of relevance to Parkinson's disease. Chemical Research in Toxicology, 9, pp. 1117-1126.
37. Sidell, K.R. and Olson, S.J. and Ou, J.J. and Zhang, Y. and Amarnath, V. and Montine, T.J. (2001) Cysteine and mercapturate conjugates of oxidized dopamine are in human striatum but only the cysteine conjugate impedes dopamine trafficking in vitro and in vivo. Journal of Neurochemistry, 79, pp. 510-521.
38. Takahashi, H. and Snow, B. and Bhatt, M.H. and Peppard, R. and Eisen, A. and Calne, D.B. (1993) Evidence for a dopaminergic deficit in sporadic amyotrophic lateral sclerosis on positron emission scanning. Lancet, 342, pp. 1016-1018.
39. Trotti, D. and Rizzini, B.L. and Rossi, D. and Haugeto, O. and Racagni, G. and Danbolt, N.C. and Volterra, A. (1997) Neuronal and glial glutamate transporters possess an SH-based redox regulatory mechanism. The European Journal Of Neuroscience, 9, pp. 1236-1243.
40. Tse, D.C. and McCreery, R.L. and Adams, R.N. (1976) Potential oxidative pathways of brain catecholamines. Journal of Medicinal Chemistry, 19, pp. 37-40.
41. Valentine, J.S. and Hart, P.J. (2003) Misfolded Cu/Zn SOD and amyotrophic lateral sclerosis. Proceedings of The National Academy of Sciences of The United States of America, 100, pp. 3617-3622.
42. Vogels, O.J.M. and Veltman, J. and Oyen, W.J.G. and Horstink, M.W.I.M. (2000) Decreased striatal dopamine D2 receptor binding in amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA): D2 receptor down-regulation versus striatal cell degeneration. Journal of Neurological Sciences, 180, pp. 62-65.
43. Whitehead, R.E. and Ferrer, J.V. and Javitch, J.A. and Justice, J.B. (2001) Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter. Journal of Neurochemistry, 76, pp. 1242-1251.
44. Xia, X.G. and Schmidt, N. and Teismann, P. and Ferger, B. and Schulz, J.B. (2001) Dopamine mediates striatal malonate toxicity via dopamine transporter-dependent generation of reactive oxygen species and D2 but not D1 receptor activation. Journal of Neurochemistry, 79, pp. 63-70.
45. Xin, W. and Shen, W. and Dryhurst, G. (2000) Oxidative metabolites of 5-S-cysteinylnorepinephrine are irreversible inhibitors of mitochondrial complex I and the alpha-ketoglutamate dehydrogenase and pyruvate dehydrogenase complexes: Possible implications for neurodegenerative brain disorders. Chemical Research in Toxicology, 13, pp. 749-760.
46. Zhang, J. and Kravtsov, V. and Amarnath, V. and Picklo, M. and Graham, D. and Montine, T. (2000) Enhancement of dopaminergic neurotoxicity by the mercapturate of dopamine: Relevance to Parkinson's disease. Journal of Neurochemistry, 74, pp. 970-978.
47. Zhang, H. and Andrekopoulos, C. and Joseph, J. and Crow, J. and Kalyanaraman, B. (2004) The carbonate radical anion-induced covalent aggregation of human cooper, zinc superoxide dismutase, and alpha-synuclein: Intermediacy of tryptophan- and tyrosine-derived oxidation products. Free Radic Biol Med, 36, pp. 1355-1365.